Kerry Breen is a news editor at CBSNews.com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital. She covers current events, ...

Learn about Acromegaly disease, its symptoms like enlarged hands and facial features, and explore effective Acromegaly ...

After nearly two decades in the endocrine scene, Crinetics is making its commercial debut with the approval of a game-changing treatment for the rare growth disorder acromegaly. The FDA on Thursday ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved paltusotine for first-line treatment of patients with acromegaly who did not respond to or ...

SAN FRANCISCO—People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general ...

Patients with acromegaly had significantly higher odds of developing leukemia/lymphoma or ovarian, breast, lung, or other cancers, many of which occurred at younger ages than typically seen in the ...

Paltusotine is the first once-daily oral therapy approved for acromegaly, offering a non-invasive alternative to injections. PATHFNDR-1 and PATHFNDR-2 trials showed significant efficacy in IGF-1 ...

Bone health is critically influenced by the balance of growth hormone signalling, with both growth hormone deficiency (GHD) and acromegaly demonstrating significant but contrasting impacts on the ...

We recently published 10 Big Names With Explosive Gains That Investors Can’t Ignore. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the companies that soared by double- and triple-digits last ...

"September 25, 2025 was a historic day for Crinetics with the approval of Palsonify for the treatment of people with acromegaly,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of ...

The investigational GLP-1 receptor agonist MET-097i, which may be able to be dosed just once a month, yielded weight loss of up to 14.1% by week 28 with class-leading tolerability in a phase IIb trial ...